Conditions we treat
You’ve spent years being dismissed. These conditions are real. And there’s evidence LDN can help.
Naltra specialises in four chronic illness conditions where Low Dose Naltrexone has the strongest evidence base — and where patients face the longest waitlists, the most dismissal, and the fewest treatment options.
Fibromyalgia
Fibromyalgia
Your pain is real. You’re not imagining it. And there’s a reason your current treatment isn’t working.
Fibromyalgia is a disorder of central sensitisation — your nervous system has learned to amplify pain signals. The result is widespread pain, fatigue, cognitive fog, and sleep disruption that most GPs are ill-equipped to treat effectively. Most patients are offered antidepressants or painkillers that address the symptoms without touching the underlying mechanism. LDN works differently — by modulating the microglial activity that drives central sensitisation, it addresses the mechanism rather than just masking the output.
Widespread pain
Fatigue
Brain fog
Sleep disruption
Headaches
IBS symptoms
Sensitivity to touch
Why LDN helps
Stanford University ran double-blind placebo-controlled trials showing LDN reduced fibromyalgia pain scores by 30% versus placebo — with minimal side effects and no dependency risk. The key is proper titration to your therapeutic dose. Most patients prescribed LDN are underdosed and never reach it.
10M
Americans affected
MCAS
Mast Cell Activation Syndrome
You react to everything. Food, smells, stress, temperature. And nobody could tell you why.
MCAS occurs when mast cells — immune cells that release inflammatory mediators — become chronically overactive, triggering reactions across multiple body systems. Symptoms are wide-ranging and often bizarre, which is why patients spend years being told their reactions are anxiety or psychosomatic. MCAS is massively underdiagnosed and frequently co-occurs with fibromyalgia, POTS, and hypermobility. LDN’s immune-modulating properties directly address mast cell hyperactivation — and when combined with ketotifen, the dual approach targets both the downstream histamine response and the upstream mast cell activity.
Chronic nausea
Flushing
Hives
Brain fog
Abdominal pain
Anaphylaxis risk
Fatigue
Reactions to food
Why LDN + ketotifen helps
LDN’s anti-inflammatory mechanism calms mast cell overactivity at a systemic level. Ketotifen — which is not commercially available in oral form in the US and must be compounded — provides dual action as both an H1 antihistamine and a mast cell stabiliser. Together they address MCAS from two angles simultaneously. Naltra compounds both through our certified pharmacy partner.
17M
estimated US patients
ME/CFS
ME/CFS
You’re not tired. You’re ill. And exercise doesn’t help — it makes it worse.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is a serious, complex, multi-system illness characterised by profound fatigue that doesn’t improve with rest, post-exertional malaise that can last days or weeks after minimal activity, and cognitive impairment that can be severely disabling. ME/CFS has historically been dismissed as psychological or exaggerated. Current research points clearly to neuroinflammation and immune dysregulation as the underlying mechanisms — which is precisely where LDN acts. 67% of patients in one ME/CFS cohort study reported meaningful improvement on LDN.
Post-exertional malaise
Profound fatigue
Cognitive impairment
Sleep dysfunction
Orthostatic intolerance
Pain
Why LDN helps
LDN addresses neuroinflammation and microglial dysfunction — mechanisms now understood to be central to ME/CFS pathology. There are no FDA-approved treatments for ME/CFS. LDN is one of the most discussed evidence-based interventions in ME/CFS clinical communities, and one of the most prescribed by the small number of specialists who understand the condition.
3.3M
Americans affected
Long COVID
Long COVID
You recovered from COVID. But you never got better.
Long COVID affects an estimated 1 in 6 people who contract COVID-19 — producing symptoms that persist for months or years after the acute infection resolves. The symptom profile overlaps almost entirely with ME/CFS, MCAS, and POTS: fatigue, brain fog, post-exertional malaise, autonomic dysfunction, and mast cell hyperactivation. Many long COVID patients meet diagnostic criteria for ME/CFS or MCAS. There is no FDA-approved treatment. LDN is one of the most studied and most discussed interventions in the long COVID clinical community, with a growing evidence base specifically targeting the neuroinflammatory and immune mechanisms driving the condition.
Fatigue
Brain fog
Breathlessness
Post-exertional malaise
POTS symptoms
Mast cell symptoms
Sleep disruption
Why LDN helps
A 2026 comprehensive review across 105 studies includes long COVID as a key indication for LDN, specifically covering its role in post-infectious neuroinflammatory syndromes. The Solve ME/CFS Initiative published formal guidance in 2026 on LDN as a rationale-supported intervention for long COVID and ME/CFS.
15M
Americans affected
Not sure if your condition qualifies?
Complete your intake and a clinician will review whether LDN is appropriate for your specific situation. No commitment until you decide to proceed.
See if LDN is right for me →
Clinical review within 48 hours · All 50 states · $149/month